RECALL PROCEDURES FOR HYBRID PRODUCTS: REGULATORY FRAMEWORK, PRODUCT SAFETY AND LEGAL ACCOUNTABILITY

1. INTRODUCTION

Recall procedures for hybrid products are an essential component of pharmaceutical regulation, biotechnology governance and public health protection. Hybrid products are products that combine two or more technological or therapeutic components, such as a medicinal substance and a medical device, a biological product and a delivery system, or a drug combined with a diagnostic or monitoring component.

Examples include drug-device combination products, prefilled medicinal delivery systems, drug-eluting implants, certain biologic-device combinations and advanced therapeutic products incorporating specialised delivery technologies.

Although these products provide significant medical benefits, their combined components may create complex safety risks. A defect in one component may affect the safety, effectiveness or performance of the entire product.

A recall is therefore a regulatory and corrective mechanism through which defective, unsafe, improperly manufactured or non-compliant products are removed from distribution, corrected, replaced or otherwise controlled.

The primary objectives are to protect patients, prevent further exposure, ensure traceability and establish accountability throughout the product supply chain.

2. MEANING AND SCOPE OF HYBRID PRODUCT RECALLS

A hybrid product recall refers to the organised removal, correction or withdrawal of a product that combines different therapeutic or technological components when it presents an unacceptable safety, quality, performance or regulatory compliance concern.

Hybrid products may include:

Drug-device combination products.

Biological products incorporating delivery devices.

Drug-eluting medical implants.

Medicinal products supplied with integrated diagnostic devices.

Products combining biological materials with engineered delivery systems.

Certain advanced therapy medicinal products incorporating device components.

The recall must consider the complete product rather than examining each component independently.

For example, a defective delivery mechanism may prevent a medicinal product from delivering its intended dose, even where the medicinal formulation itself satisfies its quality specifications.

Similarly, a manufacturing defect in a medicinal component may compromise an otherwise properly functioning medical device.

3. MAJOR REASONS FOR RECALLING HYBRID PRODUCTS

Hybrid products may require recall for several reasons:

A. Manufacturing defects: Defective assembly, contamination, inconsistent manufacturing quality or failure to comply with approved specifications.

B. Device malfunction: Failure of an integrated delivery mechanism, monitoring component or other essential device functionality.

C. Pharmaceutical quality defects: Incorrect formulation, impurities, inadequate stability or failure to meet approved quality standards.

D. Biological safety concerns: Unexpected adverse reactions, contamination or other safety problems involving biological components.

E. Labelling and packaging errors: Incorrect instructions, missing warnings, inaccurate dosage information or inadequate storage information.

F. Post-market safety signals: Serious adverse events, unexpected clinical outcomes or newly identified risks that materially affect the product's benefit-risk assessment.

G. Regulatory non-compliance: Manufacture, distribution or marketing contrary to applicable approvals, licences or statutory requirements.4. INDIAN REGULATORY FRAMEWORK

A. Drugs and Cosmetics Act, 1940

The Act establishes the regulatory framework for the manufacture, import, distribution and sale of pharmaceutical products. Its provisions are relevant to hybrid products containing medicinal or biological components.

Section 26A empowers the Central Government to regulate, restrict or prohibit the manufacture, sale or distribution of drugs in the public interest.

B. Medical Devices Rules, 2017

Rule 89 is particularly important. It requires manufacturers or authorised agents who believe that a medical device may be unsafe to immediately initiate withdrawal procedures from the market and patients and inform the competent authority.

The manufacturer must cooperate with regulators and communicate the measures taken to prevent risks to patients. This is a specific statutory recall obligation for regulated medical devices. <Cite refs={["turn965131search0","turn965131search4"]}/>

C. CDSCO Recall and Rapid Alert Guidelines, 2024

The Central Drugs Standard Control Organisation issued revised Guidelines on Recall and Rapid Alert System for Drugs, including Biologicals and Vaccines, effective from 18 July 2024.

The guidelines cover quality defects and reported safety and efficacy incidents. They apply to manufacturers, importers, exporters, stockists, distributors and retailers.

They recognise voluntary and statutory recalls and establish risk-based recall classifications. <Cite refs={["turn813919view0"]}/>

D. Consumer Protection Act, 2019

Sections 82–87 establish the product liability framework. Manufacturers, product service providers and sellers may face liability where statutory requirements are satisfied.

E. Drugs and Cosmetics Rules, 1945

The applicable manufacturing licence conditions and Schedule M requirements address complaints, defective products, distribution records and recall arrangements.

An important distinction is that India does not have one universal recall procedure covering every hybrid product. The applicable regulatory route depends on the product's legal classification and the medicinal, biological and device components involved.

5. STEP-BY-STEP RECALL PROCEDURE

1. Identification of the defect

The manufacturer identifies the potential safety or quality problem through adverse-event reports, complaints, inspections, stability studies or post-market surveillance.

2. Risk assessment

The manufacturer evaluates the seriousness of the defect, affected population, possible injuries and consequences of continued use.

3. Recall decision

The manufacturer determines whether voluntary recall is necessary. Regulatory authorities may also direct a statutory recall.

4. Notification of authorities

The manufacturer or authorised representative informs the competent regulatory authority and supplies relevant product, batch and distribution information.

5. Suspension of distribution

Further distribution and sale of affected stock must be stopped. Warehouses, distributors and retailers receive appropriate recall instructions.

6. Patient and healthcare professional notification

Where necessary, hospitals, doctors, pharmacies and affected patients receive safety notices explaining the risks and required corrective measures.

7. Recovery and reconciliation

Affected products are recovered, identified and reconciled against distribution records.

8. Investigation and corrective action

The manufacturer investigates the root cause and implements corrective and preventive actions (CAPA).

9. Final disposal and recall closure

Recalled products are securely segregated and disposed of, corrected or otherwise handled in accordance with regulatory requirements. Recall effectiveness must be documented.

6. RECALL CLASSIFICATION AND TIMELINES

Under the CDSCO 2024 drug recall guidelines, recalls are classified according to the potential health consequences.

Class I recalls extend to consumers, retailers and wholesalers, with public announcements. Class II recalls extend to retail and wholesale levels, while Class III recalls extend to wholesale level.

These are CDSCO guideline timelines for drug recalls, not a replacement for the immediate recall obligation under Rule 89 of the Medical Devices Rules. <Cite refs={["turn702554view0","turn702554view1"]}/>

7. RELEVANT CASE LAWS

1. Mrs. Lalita Rajpurohit v. M/s Johnson & Johnson Ltd. & Others, Consumer Case No. 233 of 2013, NCDRC, 3 September 2024

<text color="success" weight="medium" size="xs">DIRECT FACTUAL AUTHORITY</text>

The case concerned defective ASR metal-on-metal hip implants manufactured by DePuy and marketed by Johnson & Johnson. The implants had been voluntarily recalled globally following concerns about increased revision surgery rates and adverse reactions.

The NCDRC found evidence of inherent manufacturing defects and harmful metal debris. It partly allowed the complaint and directed the manufacturers to pay Rs. 35 lakh jointly and severally, with 6% annual interest, subject to adjustment of compensation already paid.

Relevance: This is a significant Indian consumer adjudication concerning defective medical implants, recall responsibilities and compensation for affected patients. <Cite refs={["turn581717view1","turn813823view1"]}/>

2. Usha Gupta v. M/s Johnson & Johnson Ltd. & Others, Consumer Case No. 302 of 2015, NCDRC, 3 September 2024

<text color="success" weight="medium" size="xs">DIRECT FACTUAL AUTHORITY</text>

This case also concerned complications associated with ASR XL hip implants and the manufacturer's recall and remedial measures.

Relevance: It illustrates the importance of patient follow-up, medical monitoring, disclosure of risks and evidence concerning the consequences of defective implanted products. <Cite refs={["turn581717view0"]}/>

3. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

<text color="secondary" size="xs" weight="medium">ANALOGOUS AUTHORITY</text>

The Supreme Court explained the applicability of consumer protection legislation to medical services.

Relevance: Deficiencies in healthcare services associated with recalled hybrid products may give rise to consumer remedies where statutory requirements are satisfied.

4. Spring Meadows Hospital v. Harjol Ahluwalia (1998) 4 SCC 39

<text color="secondary" size="xs" weight="medium">ANALOGOUS AUTHORITY</text>

The Supreme Court examined medical negligence and consumer liability in circumstances involving serious patient injury.

Relevance: Hospitals and healthcare professionals must exercise appropriate care when using medical products and responding to known safety warnings.

5. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

<text color="secondary" size="xs" weight="medium">ANALOGOUS AUTHORITY</text>

The Supreme Court discussed the legal standards for establishing professional medical negligence.

Relevance: A healthcare provider's failure to respond appropriately to a known product defect may raise questions of professional negligence, depending on the evidence.

6. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

<text color="secondary" size="xs" weight="medium">ANALOGOUS AUTHORITY</text>

The Supreme Court established important principles concerning informed medical consent.

Relevance: Patients must receive appropriate information about material risks, replacement procedures and treatment alternatives when a recalled hybrid product affects their ongoing care.

8. INSTITUTIONAL RESPONSIBILITIES AND COMPLIANCE

Effective recall governance requires:

Manufacturers must maintain written recall procedures and traceability records.

Regulatory authorities must investigate serious defects and enforce applicable recall requirements.

Hospitals must identify affected patients and coordinate appropriate clinical follow-up.

Distributors must stop further distribution and maintain return records.

Healthcare professionals must communicate relevant safety warnings to patients.

Quality assurance departments must investigate root causes and document CAPA.

Manufacturers must conduct mock recalls to assess the effectiveness of recall arrangements.

The CDSCO 2024 guidelines specifically require mock recalls and documented evaluation of recall effectiveness. <Cite refs={["turn702554view2"]}/>

9. LEGAL CONSEQUENCES OF FAILURE TO RECALL

Failure to initiate or properly execute a legally required recall may result in:

Regulatory enforcement and suspension or cancellation of relevant licences.

Criminal prosecution where statutory offences are established.

Product liability claims under the Consumer Protection Act, 2019.

Compensation for physical injury and financial loss.

Civil liability for negligence or failure to warn.

Corrective directions and restrictions on further distribution.

Corporate accountability where the applicable legal requirements are satisfied.

10. CONCLUSION

Recall procedures for hybrid products are essential for protecting patients from defective medicines, biological components and medical devices. Their complexity requires a coordinated regulatory approach covering the entire product rather than considering individual components in isolation.

India's Medical Devices Rules, 2017, particularly Rule 89, and the CDSCO Recall and Rapid Alert Guidelines, 2024, provide important mechanisms for product withdrawal, risk classification, notification, investigation and corrective action.

The NCDRC's decision in Lalita Rajpurohit v. Johnson & Johnson Ltd. provides a particularly relevant factual precedent demonstrating the legal consequences associated with defective implanted medical products and inadequate patient protection.

Ultimately, an effective recall system requires early identification, prompt regulatory notification, complete supply-chain traceability, patient communication, compensation where legally justified and long-term post-recall monitoring. Public health protection must remain the primary consideration throughout the product lifecycle.